CanRIO Member Publications

CMAJ 2020 Immune checkpoint inhibitors (ICI’s) are increasingly used in cancer immunotherapy, and have shown unprecedented survival benefit in a number of malignancies with historically… Read More

Ann Rheum Dis 2020 Background: Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given… Read More

Cancer Immunol Immunother 2021
Limited data are available on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with preexisting autoimmune diseases… Read More

Nat Rev Clin Oncol 2020
The enhancement of immune responses upon treatment with immune checkpoint inhibitors can have the desired outcome of reinvigorating antitumour… Read More

N Engl J Med 2020
A case description of the successful use of tofacitinib in a patient with gastric cancer receiving pembrolizumab whose… Read More

Sci Rep 2020
The ‘real-world’ patient population of metastatic melanoma is not fully represented in clinical trials investigating checkpoint inhibitors. We described therapy discontinuation… Read More

Autoimmun Rev 2020
Objective: Although immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, their use is associated with immune toxicities referred to as immune-related… Read More

J Rheum 2019
Immune checkpoint inhibitors have revolutionized cancer therapy by blocking inhibitory pathways of the immune system to fight cancer cells. Their use… Read More

CMAJ 2019
Inhibitors against cytotoxic T-lymphocyte--associated protein 4 and programmed cell death 1 immune checkpoints are novel agents that modulate immune pathways and enhance… Read More

Clin Rheumatol 2019
Immunotherapy for cancer treatment continues to evolve, and immune checkpoints have proven successful therapeutic targets. With success has come the challenge… Read More